source
- Alnylam’s stock continues to fall as weekly roundup highlights Q2 earnings across biopharmaThe August 1 edition of Endpoints Weekly opens with a look at the latest biopharma earnings season. Alnylam Therapeutics is highlighted for a continued decline in its share price, reflecting ongoi…
- Novo Nordisk's late-stage anti-inflammatory heart drug fails Phase 3 trialNovo Nordisk announced that its experimental anti-inflammatory compound designed to target cardiovascular inflammation did not meet its primary endpoint in a Phase 3 trial. The study was intended…